BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, November 22, 2024
See today's BioWorld
Home
» BBI outpaces NBI and DJIA amidst CRLS, Q3 results
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
BioWorld Biopharmaceutical Index (BBI)
BBI outpaces NBI and DJIA amidst CRLS, Q3 results
Nov. 6, 2023
By
Amanda Lanier
No Comments
The BioWorld Biopharmaceutical Index (BBI) fell through October, ending the month up just 0.98%. It remains above its low point of the year, when it was down 3.65% at the end of February.
BioWorld
Analysis and data insight